CLINICAL TRIALS PROFILE FOR TREMELIMUMAB-ACTL
✉ Email this page to a colleague
All Clinical Trials for tremelimumab-actl
| Trial ID | Title | Status | Sponsor | Phase | Start Date | Summary |
|---|---|---|---|---|---|---|
| NCT00378482 ↗ | A Rollover Study for Patients Who Received Tremelimumab in Other Protocols, to Allow the Patients Access to Tremelimumab Until This Agent Becomes Commercially Available or Development is Discontinued. | Active, not recruiting | AstraZeneca | Phase 2 | 2007-03-05 | This study is intended to provide access to tremelimumab for patients who have previously received tremelimumab in a clinical trial. |
| NCT00702923 ↗ | CP-675,206 in Combination With Short Term Androgen Deprivation in Patients With Stage D0 Prostate Cancer | Terminated | Pfizer | Phase 1 | 2008-07-01 | The current protocol will evaluate the safety of combining treatment with bicalutamide(Casodex) and CP-675,206 (anti-CTLA-4 monoclonal antibody) in patients with PSA-recurrent non-metastatic (stage D0) prostate cancer. This is a dose escalation study with safety the primary endpoint. Secondary endpoints will be to determine whether prostate associated immune responses are seen, and whether treatment is associated with an increase in PSA doubling time and PSA recurrence at one year, as markers of clinical activity. Cohorts of six patients will be treated in each dose level. The investigators hypothesize that short-term androgen deprivation therapy will elicit prostate cancer-associated T-cell mediated tissue destruction that can be augmented with a monoclonal antibody blocking CTLA-4, and that this will have therapeutic benefit in patients with recurrent prostate cancer. |
| NCT00702923 ↗ | CP-675,206 in Combination With Short Term Androgen Deprivation in Patients With Stage D0 Prostate Cancer | Terminated | University of Wisconsin, Madison | Phase 1 | 2008-07-01 | The current protocol will evaluate the safety of combining treatment with bicalutamide(Casodex) and CP-675,206 (anti-CTLA-4 monoclonal antibody) in patients with PSA-recurrent non-metastatic (stage D0) prostate cancer. This is a dose escalation study with safety the primary endpoint. Secondary endpoints will be to determine whether prostate associated immune responses are seen, and whether treatment is associated with an increase in PSA doubling time and PSA recurrence at one year, as markers of clinical activity. Cohorts of six patients will be treated in each dose level. The investigators hypothesize that short-term androgen deprivation therapy will elicit prostate cancer-associated T-cell mediated tissue destruction that can be augmented with a monoclonal antibody blocking CTLA-4, and that this will have therapeutic benefit in patients with recurrent prostate cancer. |
| NCT00880854 ↗ | Study of CP-675,206 in Bacillus Calmette-Guerin (BCG)-Resistant Bladder Cancer | Withdrawn | Pfizer | Phase 1 | 2009-06-01 | The purpose of this study is to find out the highest safe dose of the investigational drug CP-675,206 when given in combination with BCG therapy to patients who have experienced recurrent superficial bladder cancer after standard BCG treatment. In addition, the study will look to see if taking CP 675,206 generates an immune response and evaluate how the drug affects superficial bladder cancer. |
| NCT00880854 ↗ | Study of CP-675,206 in Bacillus Calmette-Guerin (BCG)-Resistant Bladder Cancer | Withdrawn | University of Wisconsin, Madison | Phase 1 | 2009-06-01 | The purpose of this study is to find out the highest safe dose of the investigational drug CP-675,206 when given in combination with BCG therapy to patients who have experienced recurrent superficial bladder cancer after standard BCG treatment. In addition, the study will look to see if taking CP 675,206 generates an immune response and evaluate how the drug affects superficial bladder cancer. |
| NCT01649024 ↗ | A Clinical Study With Tremelimumab as Monotherapy in Malignant Mesothelioma | Unknown status | Azienda Ospedaliera Universitaria Senese | Phase 2 | 2009-05-01 | The study is designed to define the immunologic and clinical activity of Tremelimumab in patients with advanced mesothelioma. |
| >Trial ID | >Title | >Status | >Sponsor | >Phase | >Start Date | >Summary |
Clinical Trial Conditions for tremelimumab-actl
Condition Name
Clinical Trial Locations for tremelimumab-actl
Trials by Country
Clinical Trial Progress for tremelimumab-actl
Clinical Trial Phase
Clinical Trial Sponsors for tremelimumab-actl
Sponsor Name
